Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

6,047 total articles

Micron's AI Memory Boom: Buy the Dip While Supply Still Controls the Cycle

Micron's AI Memory Boom: Buy the Dip While Supply Still Controls the Cycle

Micron is trading well below its recent highs after a market pullback, but underlying fundamentals - low leverage, double-digit free cash flow, and sold-out HBM capacity - look very similar to the early stages of Nvidia's profit re-rating. This is a tradeable long: enter at $405.00, stop at $360.00, target $550.00 over a long-term, 180 trading day …

TRIN: High-Yield BDC With Income Support and Reprice Potential

TRIN: High-Yield BDC With Income Support and Reprice Potential

Trinity Capital (TRIN) offers a compelling income entry today: a monthly $0.17 dividend (14%+ yield) backed by a growing investment book, modest valuation (P/B ~1.07, P/E ~7.3) and a market cap around $1.2B. The trade targets mean reversion toward recent highs while collecting outsized cash distribution; downside is controlled with a sub-$13 stop i…

Apogee Therapeutics: Betting on Twice-Yearly Dosing to Reprice a Biotech

Apogee Therapeutics: Betting on Twice-Yearly Dosing to Reprice a Biotech

Apogee Therapeutics (APGE) is a clinical-stage biotech that just put itself squarely in the market's spotlight: compelling 16-week Phase 2 data, a long half-life TSLP program enabling infrequent dosing, and a 52-week APEX readout on 03/23/2026. This trade idea lays out a defined long with entry, stop and target for a long-term swing (180 trading da…

Lyell Immunopharma: Promising CAR-T Data, Time to Trade More Precisely

Lyell Immunopharma: Promising CAR-T Data, Time to Trade More Precisely

Lyell's dual-targeting CAR-T (ronde-cel / LYL314) has delivered impressive early response data and the company just closed a $50M tranche that extends runway into Q2 2027. The story remains fundamentally attractive, but the path to commercialization and financing risk keep this a high-volatility trade. We outline a tactical long with strict stops a…

Why SoFi Could Snap Back From a Brutal Reset: A Measured Long Trade

Why SoFi Could Snap Back From a Brutal Reset: A Measured Long Trade

SoFi (SOFI) has been punished recently by a secondary offering, a high-profile short report and crypto-related headline risk. The business, however, still posted $3.61B in 2025 revenue (+35% YoY), 13.7M members (+35%) and reported GAAP profitability across recent quarters. With a market cap near $21.9B, conservative leverage and insider buying, the…

Cloudflare: I Bought at $170 — My Next Add Is at $210 (Target $260)

Cloudflare: I Bought at $170 — My Next Add Is at $210 (Target $260)

Cloudflare is expensive on headline multiples, but its role as global edge infrastructure and recent momentum make a tactical add attractive. I personally loaded at $170 and plan to add if shares pull back to $210, with a stop at $195 and a primary target near the 52-week high at $260. The trade is driven by accelerating enterprise deal flow, impro…

NVDA: Market Pessimism Looks Overdone - A Mid‑Term Long Trade

NVDA: Market Pessimism Looks Overdone - A Mid‑Term Long Trade

Nvidia remains the engine of the AI data-center cycle: $4.33T market cap, exceptional ROE and free cash flow, and low leverage. Near-term selling has pushed momentum indicators into neutral-to-bearish territory, but fundamentals and catalysts (AI demand, new energy partnerships, industry spend signals) argue for a mid-term rebound. I outline a clea…

Buy the Discount, But Watch the Balance Sheet: XPLR Infrastructure as a Levered Play on the Energy Transition

Buy the Discount, But Watch the Balance Sheet: XPLR Infrastructure as a Levered Play on the Energy Transition

XPLR Infrastructure (XIFR) is trading at a steep price-to-book discount (P/B ~0.29) despite owning contracted battery, solar, and wind cash flows. The equity looks actionable as a long-term trade around $10.10, but heavy leverage (debt-to-equity ~1.98), negative free cash flow, and active securities litigation mean this is a conditional opportunity…

Buy Blue Owl (OWL) Around $9 — Collect a ~10% Yield While the Private-Credit Panic Runs Its Course

Buy Blue Owl (OWL) Around $9 — Collect a ~10% Yield While the Private-Credit Panic Runs Its Course

Blue Owl’s shares trade near $9 with a headline dividend yield close to 10% after a private-credit liquidity scare. The pullback is painful but targeted liquidity management, large market cap scale ($14.24B) and recent management actions create a defined asymmetric trade: collect high current yield while risking limited capital if stress stabilizes…

Kits Eyecare: Buy the Dip After a Disorderly Sell-Off

Kits Eyecare: Buy the Dip After a Disorderly Sell-Off

Kits Eyecare has been punished in recent sessions despite a business model with recurring revenue, health-care defensive characteristics, and multiple operational levers to restore profitability. With liquidity thin and sentiment weak, a disciplined long entry offers asymmetric upside versus defined downside risk. This trade idea lays out entry, st…

Why Amazon Could Finally Neutralize Anthropic — and How to Trade It

Why Amazon Could Finally Neutralize Anthropic — and How to Trade It

Amazon's AWS looks positioned to fold OpenAI-model access and Nvidia GPU economics into a unified enterprise stack, cutting Anthropic out of critical enterprise lanes. This trade targets a re-rating driven by higher AI-related revenue capture and improved incremental margins. Entry, stop and target are laid out with a clear 180-trading-day horizon …

Novo Nordisk: Short the Complacency — Priced For Disaster

Novo Nordisk: Short the Complacency — Priced For Disaster

Novo Nordisk looks dangerously exposed: cheap semaglutide generics from India, a troubled pipeline headline and stretched capital-market expectations have already crushed the stock from a $81 52-week high to the mid-$30s. Combine a heavy institutional short interest, weakening technicals and near-term legal/regulatory headlines, and you have a trad…

HBM Shortage Could Double Micron to $1 Trillion — A Trade Plan

HBM Shortage Could Double Micron to $1 Trillion — A Trade Plan

Micron is the biggest pure-play memory beneficiary of an HBM shortage tied to AI infrastructure. Strong revenue/earnings beats, robust free cash flow and low leverage support a bull case that could take the stock to ~$890 (implied $1T market cap). Trade plan provided with entry at $416.00, stop at $360.00 and a long-term target of $890.00 (180 trad…